AC
SWTX

Athanor Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Athanor Capital’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,489
Closed -$1.27M – 1035
2020
Q4 		$1.27M Sell
17,489
-2,901
-14% -$187K 0.03% 261
2020
Q3 		$972K Sell
20,390
-16,181
-44% -$689K 0.04% 242
2020
Q2 		$1.54M Buy
36,571
+22,265
+156% +$792K 0.08% 135
2020
Q1 		$386K Sell
14,306
-16,206
-53% -$528K 0.03% 137
2019
Q4 		$1.17M Buy
+30,512
New +$714K 0.05% 141

Other funds holding SWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Athanor Capital's SWTX Position: Q1 2021 in Review

Athanor Capital sold out of SpringWorks Therapeutics (SWTX) in Q1 2021, closing a stake of 17,489 shares — an estimated $1.27M sold.

Athanor Capital first reported a position in SWTX in Q4 2019 and held it in 5 quarters. The position peaked at $1.54M in Q2 2020. 137 funds tracked by Wall St. Rank hold SWTX as of Q1 2021.

  • Athanor Capital reported no remaining SpringWorks Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 17,489 SpringWorks Therapeutics shares in Q1 2021, an estimated $1.27M.
  • Athanor Capital first reported a position in SpringWorks Therapeutics in Q4 2019 and held it in 5 quarters.
  • Athanor Capital's SpringWorks Therapeutics position peaked at $1.54M in Q2 2020.
  • 137 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.